Nationwide Survey for Acute Liver Failure and Late-Onset Hepatic Failure in Japan
AASLD LiverLearning®, Nobuaki Nakayama, 194816
Treatment of hepatitis C patients in a public health care setting with sofosbuvir-based treatment regimens: Efficacy and safety in real-life in Punjab, India
AASLD LiverLearning®, Radha Dhiman, 195072
Sexual dimorphism in liver ischemia and reperfusion injury in mice: Role of male-specific gene SRY
AASLD LiverLearning®, Jian Dong, 194817
High efficacy of the currently recommended regimens of 2 Direct Acting Antivirals (DAAs) + Ribavirin (R) in HCV genotype 4 (GT4) patients (pts) with advanced fibrosis or cirrhosis in HERACLIS real world cohort
AASLD LiverLearning®, IOANNIS GOULIS, 195073
Serial Procalcitonin Levels in Patients with Acute Liver Failure
AASLD LiverLearning®, Jody Rule, 194818
Molecular Mechanisms of Recovery from Ethanol-Induced Steatosis after Ethanol Withdrawal
AASLD LiverLearning®, Paul Thomes, 194831
Quality of life in HCV patients treated with Ombitasvir/Paritaprevir/r ± Dasabuvir ± Ribavirin under real-life conditions - data from the German observational study LIFE-C
AASLD LiverLearning®, Kristina Lohmann, 195087
Genomic and transcriptomic analysis reveal a driving role of TGF-β signaling in suppressing alcohol induced liver injury and HCC
AASLD LiverLearning®, Shuyun Rao, 194832
Patient-Reported Quality of Life Improves After Treatment of Hepatitis C with Direct-Acting Anti-Virals: A Real-World Experience
AASLD LiverLearning®, Robert Mitchell, 195088
PDE4 Inhibitor Attenuates Liver Injury In Alcoholic Hepatitis Model: Use Of Novel Drug Carrier System For Targeted Delivery
AASLD LiverLearning®, Leila Gobejishvili, 194833
The real-world efficacy, changes in liver stiffness values and fibrosis markers, and the safety of daclatasvir plus asunaprevir used to treat patients with HCV genotype 1b infection
AASLD LiverLearning®, Hye Won Lee, 195089
Impaired TFEB-Mediated Lysosomal Biogenesis Contributes to Acute-on-Chronic Alcohol-Induced Liver Injury in Mice
AASLD LiverLearning®, Wen-Xing Ding, 194834
Identification and novel mechanisms of elevated CYP2E1 and other P450 isoforms in circulating extracellular vesicles from alcoholic patients and alcohol-exposed rodents through increased oxidative and ER stress
AASLD LiverLearning®, Young-Eun Cho, 194847
Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.
AASLD LiverLearning®, Omar El-Sherif, 195103
Ethanol induced hepatic exosomes mediate impaired skeletal muscle signaling responses in myotubes and contribute to sarcopenia in alcoholic liver disease.
AASLD LiverLearning®, Srinivasan Dasarathy, 194848
Worldwide Lack of Early Referral of Patients with Alcoholic Liver Disease: Final Results of the Global Alcoholic Liver Disease Survey (GLADIS)
AASLD LiverLearning®, Neil Shah, 194849
Prevalence and Factors Associated with Detectable Viral Load at End of Treatment in Direct-Acting Antiviral (DAA)-Treated Patients: Implications for Guidance on HCV RNA Monitoring During Treatment
AASLD LiverLearning®, Kavita Radhakrishnan, 195105
Phosphoprotein Profiling Indicates Markers of Hepatic DNA Damage and ATM Pathway Activation Separate Hepatic Injury in NASH from Fatty Liver
AASLD LiverLearning®, Preeti Viswanathan, 194850
Ethanol Induces ATM-mediated DNA Damage Response along with Additional Oxidative DNA Damage and Mitochondrial Injury that is Amenable to Receptor-mediated Therapeutics
AASLD LiverLearning®, Yogeshwar Sharma, 194863
Evolution of thrombocytopenia in patients with hepatitis C virus infection and advanced fibrosis after treatment with direct antiviral agents.
AASLD LiverLearning®, Judith Gomez-Camarero, 195119
Alcohol Liver Disease is now the most rapidly rising Indication for Liver Transplant Waitlist Registration in the United States
AASLD LiverLearning®, George Cholankeril, 194864
Real-World Experiences with Direct-Acting Antivirals for Hepatitis C Treatment
AASLD LiverLearning®, Kimberly Daniel, 195120
Role of Serum Zinc And Polyunsaturated Fatty Acids In The Exacerbation Of Liver Injury In Treatment Naïve HIV-Infected Alcohol Dependent Patients
AASLD LiverLearning®, Vatsalya Vatsalya, 194865
Optimising the impact of direct-acting antiviral treatment in Hepatitis C: Lessons from a universal access, real-world cohort
AASLD LiverLearning®, Phoebe Thwaites, 195121
The Impact of Strength of Social Support on Alcohol Use Behaviors in Patients with Alcohol Related Cirrhosis
AASLD LiverLearning®, Patricia Ajayi-Fox, 194866
Session I Moderator
AASLD LiverLearning®, Lili Wang, 202044
Co-Transplantation of Liver Sinusoidal Endothelial Cells, Kupffer Cells and Hepatocytes Improved Cell Engraftment and Repopulation in the Mouse Liver
AASLD LiverLearning®, Ester Borroni, 194879
Safety and Efficacy of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials
AASLD LiverLearning®, Steven Flamm, 195135
Modulation of KATP Channel by Blockade of the Sulfonylurea Receptor Subunit Enhanced Engraftment and Proliferation of Transplanted Hepatocytes by Improving Mitochondrial Functionality
AASLD LiverLearning®, Fadi Jaber, 194880
A past history of HCC is not associated to worst SVR in HCV cirrhotic patients treated with DAAs: a prospective multicenter Italian study.
AASLD LiverLearning®, Savino Bruno, 195136
Age-dependent effects of intracellular ATZ protein globules on hepatocyte proliferation and ploidy in alpha-1 antitrypsin deficiency
AASLD LiverLearning®, Zahida Khan, 194881
Treatment of HCV with DAAs in cirrhosis: Risk of early de novo hepatocellular carcinoma (HCC) and impact of HCC on SVR.
AASLD LiverLearning®, Richard Sterling, 195137
Inhibition of hypoxia inducible factor via upregulation of von Hippel-Lindau protein induces 'Angiogenic switch off' in a mouse hepatoma model
AASLD LiverLearning®, Hideki Iwamoto, 194882
Cold storage of porcine hepatocytes
AASLD LiverLearning®, YI LI, 194895
Failure to multiple Interferon-free direct antiviral therapies: could chronic hepatitis C become incurable?
AASLD LiverLearning®, Johannes Vermehren, 195151
Aspirin and the Risk of Hepatocellular Carcinoma Development in Patients with Compensated Alcoholic Cirrhosis
AASLD LiverLearning®, Minjong Lee, 194896
A prospective, open-label, Multi-center study to evaluate efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in genotype 1 patients with previous protease inhibitors failure: interim analysis (The Emerald study)
AASLD LiverLearning®, Oren Shibolet, 195152
Trial Design: Phase I study to evaluate safety and anti-tumor activity of autologous T cells with alpha-feto protein (AFPc332T) receptor in patients with advanced hepatocellular carcinoma (HCC)
AASLD LiverLearning®, Rafael Amado, 194897
Feasibility and safety of concomitant antiviral therapy with DAAs and chemotherapy in patients with HCV chronic hepatitis and aggressive B-cell non-Hodgkin lymphomas
AASLD LiverLearning®, Vincenzo Occhipinti, 195153
Identification of serum cold inducible RNA-binding protein as a novel biomarker that predicts survival in patients with resectable hepatitis B-related hepatocellular carcinoma
AASLD LiverLearning®, Mengyun Ke, 194898
Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Biomarker of Hepatic Progenitor Cell/Biliary Features in Hepatocellular Carcinoma and of Prognosis
AASLD LiverLearning®, Nobuharu Tamaki, 194911
Developing A New Iodine Contrast Agent, Which Achieve Hepato-biliary Phase in CT imaging Through Hepatocyte Specific Transporters
AASLD LiverLearning®, Nobuyuki Matsumoto, 195167
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
AASLD LiverLearning®, Roniel Cabrera, 194912
Serum WFA+-M2BP Level as a Diagnostic Marker of Hepatitis B Virus-related Hepatocellular Carcinoma
AASLD LiverLearning®, Pisit Tangkijvanich, 195168
A Prognostic Impact of Fibroblast-derived Cytokine, IL-34 in Non-hepatitis B virus-, Non-hepatitis C virus-related Hepatocellular Carcinoma Patients with Chronic Liver Disease
AASLD LiverLearning®, Yu Noda, 194913
Prognostic histological factors in resected colorectal liver metastasis with preoperative treatment.
AASLD LiverLearning®, Pamela Baldin, 195169
Comparison of Determinants for Hispanic-White and Black-White Disparities in Hepatocellular Carcinoma Prognosis
AASLD LiverLearning®, Nicole Rich, 194914
Lack of evidence for increased rates of hepatocellular carcinoma following treatment with direct acting antivirals: a systematic review and meta-analysis.
AASLD LiverLearning®, Stephanie Rutledge, 194927
Outcome of liver transplant for HBV related acute-on-chronic liver failure in the era of more potent antiviral agents
AASLD LiverLearning®, Qinyang Liu, 195183
Gene expression of the NOX family members and their clinical significance in hepatocellular carcinoma
AASLD LiverLearning®, Hyuk Soo Eun, 194928
DAAs Therapy Before Liver Transplant In Patients With Hepatocellular Carcinoma And HCV Liver Disease
AASLD LiverLearning®, Candido Alcazar, 195184
Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma in Patients with Baseline Hepatitis B Virus (HBV)
AASLD LiverLearning®, Sam Misir, 194929
Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany
AASLD LiverLearning®, Kerstin Herzer, 195185
Effects of an adjuvant direct-acting antiviral drug therapy-induced sustained virological response after hepatic resection for hepatitis C virus-related solitary hepatocellular carcinoma
AASLD LiverLearning®, Shogo Tanaka, 194943
Directed Sharing to Improve Organ Allocation in the United States
AASLD LiverLearning®, Seth Karp, 195199
The impact of thyroid hormones on patients with hepatocellular carcinoma
AASLD LiverLearning®, Matthias Pinter, 194944
Diminished Survival Following Liver Transplantation For Hepatocellular Carcinoma In Patients Within Milan Criteria But Outside Total Tumor Volume/Alpha-fetoprotein Criteria
AASLD LiverLearning®, Bhavana Bhagya Rao, 195200
Nearly One in Five Hepatocellular Carcinoma (HCC) Patients in the U.S. are of Hispanic Ethnicity, But less than 40% had HCC Within Milan Criteria at Time of Diagnosis
AASLD LiverLearning®, Ann Robinson, 194945
HCC 6-Month Delay: Comparison of LSAM to Observed
AASLD LiverLearning®, David Schladt, 195201
Unexpected Hepatocellular Carcinoma (HCC) following treatment-induced HCV clearance in a VA cohort.
AASLD LiverLearning®, Alexander Monto, 194959
Role of Cardio-pulmonary Exercise Test Parameters in the Assessment of Liver Transplantation Candidates- An Australian Study
AASLD LiverLearning®, Malik Janjua, 195215
Tumor biomarkers and regorafenib (REG) efficacy in patients with hepatocellular carcinoma (HCC) in the RESORCE trial
AASLD LiverLearning®, Jordi Bruix, 194960
Using Grafts with 2 or more than 2 Bile Ducts for Living Donor Liver Transplantation - Does it affect Patient Outcome?
AASLD LiverLearning®, Dagmar Kollmann, 195216
Intratumoral Expression of Tregs Predicts Prognosis in Patients with Hepatocellular Carcinoma
AASLD LiverLearning®, Angeles Baquerizo, 194961
Roman Liver Tx Allocation: Results at 48 months of an innovative regional allocation model based on MELDNa and Donor-to-Recipient Match
AASLD LiverLearning®, Federica Ferracci, 195217
Prognosis of Patients with Non-hepatitis B virus-, Non-hepatitis C virus-related Hepatocellular Carcinoma: A Comparison with Hepatitis C virus-related Hepatocellular Carcinoma Patients
AASLD LiverLearning®, Yu Noda, 194975
Everolimus plus Sorafenib as a treatment option for hepatocellular carcinoma recurrence after liver transplantation.
AASLD LiverLearning®, Faouzi Saliba, 195231
Transarterial chemoembolization within first 3 months of sorafenib initiation improves overall survival in intermediate to advanced stage hepatocellular carcinoma: A retrospective, multi-institutional study with propensity matching
AASLD LiverLearning®, David Kaplan, 194976
Role of Liver Transplantation in Selected Older Recipients: A Large Center Cohort.
AASLD LiverLearning®, Omar Mousa, 195232
Robust efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with macroscopic vascular invasion: a comparative study with sorafenib
AASLD LiverLearning®, Niizeki Takashi, 194977
Alcohol Relapse in Patients Transplanted for Alcoholic Liver Disease: A Single Center Experience
AASLD LiverLearning®, Mohanad Al-Qaisi, 195233
Pre-transplant BALAD and BALAD-2 score to predict recurrence and survival of patients with hepatocellular carcinoma who underwent liver transplant
AASLD LiverLearning®, Nicha Wongjarupong, 194991
Donor CD163 and Nestin Positive Cells Predict Graft Functions in Living Donor Liver Transplant
AASLD LiverLearning®, Neha Nigam, 195247
Phase angle (and NOT BMI) correlates with Child Pugh class and BCLC stage among HCC patients: may it improve after nutritional support? Preliminary results.
AASLD LiverLearning®, Emanuele Rinninella, 194992
Effect of non-alcoholic fatty liver disease and metabolic risk factors on waitlist outcome in patients with hepatocellular carcinoma
AASLD LiverLearning®, Kelley Weinfurtner, 195248
Hepatocellular Carcinoma in Baby Boomers is associated with High Rates of Inpatient Morbidty and Mortality
AASLD LiverLearning®, Eric Yoo, 194993
Sustained virologic response is associated with a decreased risk of post-transplant diabetes mellitus in patients with hepatitis C
AASLD LiverLearning®, Giorgio Roccaro, 195249
Hepatocellular Carcinoma Impacts In-Hospital Mortality among Cirrhotic Patients
AASLD LiverLearning®, Mohammad Maysara Asfari, 195007
Is More Transplant Center Care Better? Geographic Proximity Is Associated With More Post Liver Transplant Visits But No Effect on Outcomes
AASLD LiverLearning®, Sunny Tao, 195263
Hepatocellular carcinoma (HCC) in multitransfused patients (pts) with thalassemia major (TM) Risk factors, characteristics and therapeutic approaches
AASLD LiverLearning®, Dimitrios Kountouras, 195008
Incidence and treatment of biopsy proven rejection in patients converted to Everolimus (EVL) after liver transplantation (LT): longterm histological data from the Everoliver multicenter observational French registry.
AASLD LiverLearning®, Faouzi Saliba, 195264
Incidence Rates of Hepatocellular Carcinoma in the United States have now Plateaued Except in Hispanic Women
AASLD LiverLearning®, Ju Dong Yang, 195009
Is Obesity associated with Increased Risk of Mortality and Re-transplantation in Liver Transplant Recipients? A Systematic Review and Meta-Analysis
AASLD LiverLearning®, Faisal Kamal, 195265
How does concomitant positive HBsAg affect the risk of hepatic metastasis- a retrospective clinical study in consecutive 4033 cases of newly-diagnosed colorectal cancer
AASLD LiverLearning®, Lei Zhao, 195023
Predictors of long-term normal histology on protocol allograft biopsies
AASLD LiverLearning®, Jeremy Rajanayagam, 195279
Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice
AASLD LiverLearning®, Takuro Uchida, 195024
Outcomes Analyses of Pediatric Acute Liver Failure (PALF) Subjects Listed for Liver Transplantation using Scientific Registry of Transplant Recipients (SRTR) Database
AASLD LiverLearning®, Sakil Kulkarni, 195280
Perlecan inhibition efficiently decreases HBV susceptibility of PHHs possibly via NTCP downregulation.
AASLD LiverLearning®, Tasuku Nakabori, 195025
Listing Hyponatremia Associated with Increased Mortality Risk in Pediatric Liver Transplant Candidates: A UNOS database analysis from 2005-2015
AASLD LiverLearning®, Mansi Amin, 195281
HLA-DRB1-DQB1 haplotypes and BTNL2 gene associate with response to a hepatitis B vaccine
AASLD LiverLearning®, Nao Nishida, 195039
High rates of osteopenia and osteoporosis in chronic hepatitis B caucasian patients untreated and treated with tenofovir disoproxil fumarate (TDF): a 4-year longitudinal cohort study
AASLD LiverLearning®, Pietro Lampertico, 195040
The expression of serum miR-125b-5p may serve as a new biomarker of the HBV-infected hepatitis progression
AASLD LiverLearning®, Masashi Ninomiya, 195041
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Korean patients with chronic HBV infection
AASLD LiverLearning®, Pil Soo Sung, 195055
Ethanol-Induced Oxidative Stress in Primary Human Hepatocytes is Suppressed by VTL C3A Cell-Secreted Factors
AASLD LiverLearning®, Jagadeesha Dammanahalli, 194800
Novel non-canonical genetic rearrangements termed “complex structural variations” in HBV genome
AASLD LiverLearning®, Kei Fujiwara, 195056
Promising effects of thymosin α1 treatment for rats with acute liver failure
AASLD LiverLearning®, Xueliang Yang, 194801
Hepatitis B Virus-specific T Cell Responses Are Regulated by Type I Interferon Signaling and Correlated with Intrahepatic Antigen Expression
AASLD LiverLearning®, Keigo Kawashima, 195057
Serotonin facilitates the concanavalin A induced acute liver injury in mice
AASLD LiverLearning®, Jianbin Bi, 194802
G-CSF administration attenuates liver injury by inhibiting hepatocyte apoptosis through Akt/Bcl2 pathway
AASLD LiverLearning®, Jinhua Hu, 194815
Efficacy and safety of direct acting antivirals (DAA) in elderly patients with cirrhosis and high comorbidity index
AASLD LiverLearning®, Sabela Lens, 195071